<DOC>
	<DOCNO>NCT00077532</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , MDX-010 , work different way stimulate immune system stop tumor cell grow . Vaccines make gp100 peptide may make body build immune response kill tumor cell . Combining vaccine Montanide ISA-51 may cause strong immune response kill tumor cell . It yet know whether monoclonal antibody therapy effective without vaccine therapy treat advanced melanoma . PURPOSE : This randomized phase II trial study monoclonal antibody therapy alone see well work compare monoclonal antibody therapy , gp100 peptide , Montanide ISA-51 treat patient stage IV melanoma .</brief_summary>
	<brief_title>Monoclonal Antibody With Without gp100 Peptides Plus Montanide ISA-51 Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine clinical response patient stage IV melanoma treat escalate dos anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody ( MDX-010 ) without gp100 peptide emulsify Montanide ISA-51 . Secondary - Determine safety toxicity profile regimens patient . - Determine immunologic response patient treat regimen . - Determine pharmacokinetics regimens patient . - Determine , HLA-A*0201-positive patient , difference responses patient previously vaccinate gp100 peptide patient previously vaccinate . OUTLINE : This 2-part , partially randomize study . - Part I ( close 3/7/2005 ) : - HLA-A*0201-negative patient : Patients receive anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody ( MDX-010 ) IV 90 minute day 1 . Treatment repeat every 3 week 6 dos ( 3 course 3 escalate dos ) absence disease progression unacceptable toxicity . - HLA-A*0201-positive patient : Patients stratify accord prior exogenous gp100 peptide immunization ( yes v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive MDX-010 manner HLA-A*0201-negative patient . - Arm II : Patients receive MDX-010 arm I . Patients also receive gp100:209-217 gp100:280-288 peptide emulsify Montanide ISA-51 subcutaneously immediately MDX-010 infusion . - Part II : - HLA-A*0201-negative patient ( close 3/7/2005 ) : Patients receive MDX-010 part I . Treatment repeat every 3 week 4 dos ( 2 course 2 escalate dos , begin high dose level part I ) absence disease progression unacceptable toxicity . - HLA-A*0201-positive patient : Patients stratify randomized part I . - Arm I : Patients receive MDX-010 manner HLA-A*0201-negative patient . - Arm II : Patients receive MDX-010 arm I . Patients also receive gp100:209-217 gp100:280-288 peptide emulsify Montanide ISA-51 subcutaneously immediately MDX-010 infusion . In part , patient stable disease complete response ( CR ) complete course MDX-010 may receive 1 additional course therapy absence unacceptable toxicity . Patients achieve partial response may continue recieve treatment MDX-010 dose , absence unacceptable toxicity , CR tumor longer shrink . Patients follow 3 week , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 35-179 patient ( 35 part I [ close 3/7/05 ] 69-141 [ 23-47 per arm ( arm I close 3/7/05 ) ] part II ) accrue study within 3-4 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV melanoma Clinically evaluable measurable disease No mucosal ocular melanoma PATIENT CHARACTERISTICS : Age 16 Performance status ECOG 02 Life expectancy At least 6 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL Hematocrit ≥ 28 % WBC ≥ 2,500/mm^3 Hepatic AST ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ ULN ( &lt; 3 mg/dL patient Gilbert 's syndrome ) Hepatitis B surface antigen negative Hepatitis C virus antibody negative Renal Creatinine &lt; 2 mg/dL Immunologic HIV negative No history follow : Inflammatory bowel disease Regional enteritis Connective tissue disorder ( e.g. , systemic lupus erythematosus ) Rheumatoid arthritis Autoimmune inflammatory eye disease Sjögren 's syndrome Inflammatory neurologic disorder ( e.g. , multiple sclerosis ) No active infection No active autoimmune disease may cause lifethreatening symptom severe organ/tissue damage Vitiligo , autoimmune thyroiditis , skin rash associate prior therapy allow patient recover grade 1 less toxicity No systemic hypersensitivity study agent Prior local reaction ( e.g. , delayed hypersensitivity glaucomatous reaction ) Montanide ISA51 gp100 injection allow No autoimmune disease require active therapy form steroid immunosuppressant Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent underlie medical condition would preclude study participation No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer , superficial bladder cancer , carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior anticytotoxic Tlymphocyteassociated antigen4 monoclonal antibody Prior therapy gp100 peptide immunotherapy allow Chemotherapy At least 6 week since prior nitrosoureas recover ( toxicity great grade 1 ) No concurrent chemotherapy Endocrine therapy At least 4 week since prior steroid No concurrent systemic , inhale , optical , topical corticosteroid Radiotherapy Not specify Surgery Not specify Other At least 3 week since prior systemic therapy melanoma recover ( toxicity great grade 1 ) No concurrent immunosuppressive agent ( e.g. , cyclosporine )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>